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There are currently no specific treatments for pachyonychia congenita (PC). Available treatments generally are
directed at specific manifestations of the disorder, and an effective treatment plan must recognize that different
patients are more or less troubled by different manifestations of the disease. Treatment for all aspects of PC has
been less than completely satisfactory. Very few studies have compared different approaches to treatment, and
fewer still have given longitudinal follow-up of efﬁcacy and patient acceptance. This review is essentially a com-
pilation of anecdotes. It was collected from physicians’ reports in the literature, from direct communication with
physicians currently following patients with PC and from patients who answered a questionnaire on the
Pachyonychia Congenita Project web page (http://www.pachyonychia.org/Registry.html).
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The goals of treatment for patients with pachyonychia con-
genita (PC) are designed to address the four major mani-
festations of the disease: (1) excess keratin accumulation in
the nail unit, the skin or the mucous membranes; (2) blisters;
(3) the pain that is associated with blisters in some, but not
in all, of the hyperkeratotic areas; (4) the keratin cysts in the
dermis. In considering therapies, it is useful to remember
that the keratins associated with PC are normally and con-
stitutively expressed in hair follicles and nails and ridged
skin of adults (Swensson et al, 1998; McGowan and Cou-
lombe, 2000); those keratins are not thought to be normally
expressed in interfollicular epidermis, but can be induced in
those locations by friction, trauma, or other acquired insult.
It remains an open question as to whether expression of
those keratins occurs in neonatal palm or sole or in palm or
sole of adults at bed rest. This implies that identification and
reduction or removal of the trauma or ‘‘insult’’ should be part
of the therapeutic regimen for palmoplantar and inter-
follicular manifestations of the disease, but might be of less
help for the hypertrophic nails and cysts. We discuss below,
general categories of treatment that have been used in PC
and then focus on treatment for specific manifestation of
the disease.
Results and Discussion
Treatment options fall into four broad categories: non-inva-
sive (mechanical), invasive (surgical), chemical, and phar-
macological. In every case, these approaches to therapy of
PC are non-specific in the sense that the same therapies
can and are used or recommended for many hyperkeratotic
problems including callosities, psoriasis, or ichthyosis. Like-
wise, strategies that reduce friction, such as those recom-
mended to patients with other mechanobullous diseases,
such as epidermolysis bullosa, are useful for many PC pa-
tients, especially those with frequent blisters.
Mechanical removal of keratin in thick nails or keratoses
has been achieved using a remarkable array of implements.
Almost all patients use some form of hand tool, such as
pumice stones, emery boards, paring knives, razor blades,
clippers, curettes, rasps, and files. Some use electrical tools,
such as table mounted or hand-held grinders, polishers, and
sanders. The importance of weight, friction, and pressure as
a co-factor in producing signs of PC is emphasized by the
many anecdotes of symptomatic improvement following
bed rest, casting for fractures and even weight loss. The old
literature has many examples of patients’ soles improving on
prolonged bed rest (Garb, 1950). Efforts to distribute weight,
pressure, and friction using specially constructed shoes, or-
thotics, insoles, or simply socks and gloves are mechanical
approaches that many patients find useful. For patients with
significant pain, crutches or a wheelchair become important
adjuncts to therapy.
Application of various chemicals to hyperkeratotic areas
has been used as monotherapy or as a preliminary step to
facilitate mechanical removal. Empirical observations have
shown that water, humectants such as urea or propylene
glycol, and weak organic acids such as salicylic and a-hy-
droxy acids all serve to facilitate removal of the outer keratin
layers. Periodic soaks in dilute bleach to reduce microbial
colonization make sense, but its usefulness has never been
proven.Abbreviation: PC, pachyonychia congenita
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Surgical approaches, including electrofulguration, deep
curettage, and excision followed by grafting of autologous
skin from an unaffected site, have been applied more suc-
cessfully to nails than to palms or soles. Keratoses recur in
transplanted skin on the soles; we could find no examples
of successful surgery for the soles.
Separate pharmacological approaches address specific
physical manifestations of PC. Systemic retinoids, including
natural vitamin A (Kelly and Pinkus, 1958), isotretinoin
(Thomas et al, 1984), and etretinate (Dupre et al, 1981;
Lucker and Steijlen, 1995), have been used to reduce
hyperkeratosis. Most patients and physicians find that re-
tinoids are effective in reducing hyperkeratosis, but that
they also can increase tenderness and blistering. It is a fact
that most patients who try retinoids do not stay on them
forever. It is not known whether acceptance could be im-
proved by empirically tailoring dosage and schedule to in-
dividual patients. At the time when phenytoin was thought
to be useful for dystrophic epidermolysis bullosa, it was also
tried in PC patients who were troubled by blisters (Blank,
1982). Few believe that it still has a place in the therapy of
PC, although one respondent to the PC Project question-
naire reports continued success in reducing blisters and
follicular hyperkeratosis using phenytoin. Levothyroxin has
been reported to help reduce blisters and hyperkeratosis in
one patient (Chowdhury and Banerjee, 1967). Secondary
infection of blister fluid, hyperkeratotic masses, or the nail
unit is an ever present danger. Culture and treatment with
appropriate anti-mycotic or anti-bacterial agents is a peri-
odic feature of the treatment regimen for many patients.
Despite apparent response to empiric antibiotic treatment,
the nature of such infections, and whether they represent
true infection or inflammatory reaction, remains to be
determined. Finally, many patients require non-narcotic
(especially non-steroidal anti-inflammatory drugs) or, occa-
sionally, narcotic analgesics for pain control; some use
topical anesthetics for painful blisters and fissures.
Certain treatments for specific manifestations of PC
warrant special comment.
Nails Nail care in PC is probably as varied as the number of
patients with the disease. Pastes of 20%–40% urea or
15%–20% salicylic acid, often applied overnight under oc-
clusion, seem to be favorite methods to soften the nails.
Appreciation that the different genes which cause PC have
slightly different patterns of expression (De Berker et al,
2000; McGowan and Coulombe, 2000) should give pause to
recommendation of a one-therapy-fits-all approach. Kera-
tins 6 and 16 appear to be constitutively expressed in sup-
rabasal cells of the ventral surface of the proximal nail fold,
in the nail bed and in the digit pulp, but not in the nail matrix.
By contrast, keratin 17 is expressed throughout the nail bed
epithelium and in the nail matrix, starting in the basal layer
(McGowan and Coulombe, 2000). This distribution of kera-
tins may explain why some surgeons have obtained satis-
factory results from ablation of the nail matrix (Thomsen
et al, 1982) whereas others have not (Cosman et al, 1964).
Perhaps Thomsen’s patient, who responded well to matrix
ablation, had a keratin 17 mutation whereas Cosman’s pa-
tient, who required nail bed ablation, had a keratin 6 or 16
mutation. The older literature describes even more aggres-
sive and drastic surgery. Distal digital amputation was felt
by one individual, reporting after a 20-y follow-up, to have
provided an overall satisfactory result (Wright, 1956).
Palms and soles Blistering, hyperkeratosis with fissuring,
and pain on the palms and soles are the main difficulties for
many patients with PC. Combinations of many of the general
classes of treatments mentioned above are used by most
patients. Many patients report hyperhidrosis as a particularly
troubling manifestation of their disease. One report indicates
that treatment of the hyperhidrosis with aluminum chloride is
effective in reducing blistering (Tidman and Wells, 1988), and
this observation goes along with the frequent report that pa-
tients are worse in summer than winter. Plantar injections of
botulinum toxin have reduced the pain and hyperkeratosis in
three patients with PC (Swartling and Vahlquist, unpublished
data). Excision and grafting of plantar skin for PC was aban-
doned years ago. Although aggressive surgical intervention
may be helpful for some inherited plantar keratodermas
(Pupo and Farina, 1953), this approach fails in PC because of
reappearance of the hyperkeratosis (Garb, 1950). A favorable
response of the plantar pain to hypnotherapy has been re-
ported in a paper that is equally interesting for its chronology
of treatments recommended for PC between 1929 and 1950
(Mullins et al, 1955).
Keratoses and itching Itching is not usually considered to
be a direct manifestation of PC, yet many patients report
that their hands and feet itch or that they itch elsewhere on
their body, for example see (Connors et al, 2001). Our un-
derstanding of the induction of the PC keratins by trauma
would suggest that this symptom should be treated, what-
ever its cause. It remains to be seen whether this symptom
will be best addressed by the use of oral antihistamines or
by topical anesthetics or steroids.
Mucous membranes Angular cheilitis and fissures are a
common complaint, usually treated with heavy emollients.
Some patients reported that brushing their tongue has a
beneficial effect on oral leukoplakia, but this has not been
studied systematically. Although it is not uncommon to
identify Candida species in leukoplakia lesions, the usual
experience is that anti-fungal agents have no effect on the
leukoplakia. By contrast, one patient reported that oral tet-
racycline had a beneficial effect on her oral leukoplakia.
Difficulty with suckling has been observed in the transgenic
mice that have absent or mutant PC-associated keratins
(Wojcik et al, 1999; Wong et al, 2000). This can be a trou-
blesome manifestation of PC in human neonates, which,
once recognized, can be managed in the neonatal period
using bottles that have free-flowing nipples and/or topical
anesthetics.
Cysts There are no reports that cysts should be treated by
any method other than those usually used for cysts: exci-
sion, incision, and drainage, hyfrecation or diathermy.
Conclusions
As we choose therapies to try in our patients, we should be
cognizant of the pathophysiological implications of a dom-
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inant-negative keratin defect. First, friction plays an impor-
tant role in all the keratin disorders. In PC, friction can be
expected to contribute to cell fragility and induce new syn-
thesis of dominant-negative keratins in cells that would not
normally express them. Therefore, it would be prudent to
avoid therapies that rely mainly on friction. Second, treat-
ments that reduce stratum corneum cohesivity should be
beneficial, as they should reduce the friction needed to re-
move excess stratum corneum. Finally, we must not under-
estimate the severity of the disability for some affected
individuals. Frequent tales of family planning that includes
decisions to have no children or to undergo prenatal or
preimplantation genetic testing are clear testimony to pa-
tients’ distress from their disease. As with all patients who
have chronic disabling, painful or disfiguring problems, ad-
equate attention to pain and depression are essential parts
of an overall treatment plan.
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